HBI Deals+Insights / M&A/IPOs
IBM is on the retreat from its decade long AI in healthcare project: a multi-billion-dollar buy-and-build strategy to gather billions of data points fed into supercomputer Watson. Critics say the business has been unprofitable, overpromised and questioned how fit for purpose it is. HBI gets the inside track.